Agios Pharmaceuticals, Inc. (AGIO) CEO Sells $2,349,200.00 in Stock
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) CEO David P. Schenkein sold 35,000 shares of the company’s stock in a transaction that occurred on Monday, September 18th. The stock was sold at an average price of $67.12, for a total value of $2,349,200.00. Following the completion of the sale, the chief executive officer now owns 35,000 shares in the company, valued at approximately $2,349,200. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
Shares of Agios Pharmaceuticals, Inc. (NASDAQ AGIO) opened at 66.07 on Friday. Agios Pharmaceuticals, Inc. has a one year low of $39.24 and a one year high of $67.74. The firm’s 50-day moving average price is $60.83 and its 200-day moving average price is $54.73. The firm’s market cap is $3.20 billion.
Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.57) by ($0.21). The business had revenue of $11.30 million during the quarter, compared to analyst estimates of $10.68 million. Agios Pharmaceuticals had a negative return on equity of 68.15% and a negative net margin of 502.12%. The company’s quarterly revenue was up 62.1% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.47) EPS. Equities research analysts expect that Agios Pharmaceuticals, Inc. will post ($7.07) earnings per share for the current fiscal year.
A number of research firms recently weighed in on AGIO. J P Morgan Chase & Co restated a “buy” rating and issued a $76.00 price target on shares of Agios Pharmaceuticals in a report on Monday, September 18th. Royal Bank Of Canada began coverage on Agios Pharmaceuticals in a report on Thursday, September 14th. They issued an “outperform” rating and a $78.00 price target on the stock. ValuEngine upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Oppenheimer Holdings, Inc. restated an “outperform” rating and issued a $83.00 price target (up previously from $75.00) on shares of Agios Pharmaceuticals in a report on Thursday, August 10th. Finally, Needham & Company LLC upped their price target on Agios Pharmaceuticals from $54.00 to $72.00 and gave the stock a “buy” rating in a report on Thursday, August 10th. Four investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $75.20.
Institutional investors have recently bought and sold shares of the business. Swiss National Bank grew its position in Agios Pharmaceuticals by 3.4% in the first quarter. Swiss National Bank now owns 55,360 shares of the biopharmaceutical company’s stock worth $3,233,000 after buying an additional 1,800 shares during the last quarter. Spark Investment Management LLC grew its position in Agios Pharmaceuticals by 139.9% in the second quarter. Spark Investment Management LLC now owns 84,700 shares of the biopharmaceutical company’s stock worth $4,357,000 after buying an additional 49,400 shares during the last quarter. Geode Capital Management LLC grew its position in Agios Pharmaceuticals by 8.3% in the first quarter. Geode Capital Management LLC now owns 263,899 shares of the biopharmaceutical company’s stock worth $15,410,000 after buying an additional 20,336 shares during the last quarter. TD Asset Management Inc. grew its position in Agios Pharmaceuticals by 4.9% in the second quarter. TD Asset Management Inc. now owns 30,000 shares of the biopharmaceutical company’s stock worth $1,544,000 after buying an additional 1,400 shares during the last quarter. Finally, Hamilton Lane Advisors LLC acquired a new position in Agios Pharmaceuticals in the second quarter worth approximately $2,890,000. Hedge funds and other institutional investors own 94.40% of the company’s stock.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.